Literature DB >> 11129183

Improved perfusion after subcritical ischemia in muscle flaps treated with vascular endothelial growth factor.

J Banbury1, M Siemionow, S Porvasnik, S Petras, E Browne.   

Abstract

Vascular endothelial growth factor (VEGF), a potent endothelial mitogen, is secreted in ischemic tissue and plays a pivotal role in angiogenesis. We studied whether VEGF administered to a rat muscle flap at the time of ischemia induction would increase microcirculatory flow to the flap. The cremaster muscle flap was isolated on its neurovascular pedicle. Ischemia was induced by clamping the vascular pedicle, and 0.2 ml of either VEGF (0.1 microg) or vehicle (phosphate-buffered saline) was immediately infused into the muscle. After 4 or 6 hours, the clamps were released, and the cremaster was placed in a pocket in the medial thigh for 24 hours. The muscle was then dissected, and microcirculatory measurements were made under intravital microscopy. Six animals were used in each of the four groups. All flaps exposed to 6 hours of ischemia, the duration considered to be critical ischemia, had no significant microcirculatory flow, regardless of treatment with VEGF. In the 4-hour ischemia group, or subcritical ischemia group, red blood cell velocity in arterioles was 14 mm/sec in muscles treated with VEGF and 9 mm/sec in controls (p = 0.02), and capillary flow was 7 per high-power field in muscles treated with VEGF versus 2 per high-power field in controls (p = 0.0005). Thus, VEGF did not alter microcirculatory flow in a muscle flap exposed to critical ischemia, but it did enhance flow to a flap exposed to subcritical ischemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129183     DOI: 10.1097/00006534-200012000-00015

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  3 in total

1.  Improved survival of ischemic cutaneous and musculocutaneous flaps after vascular endothelial growth factor gene transfer using adeno-associated virus vectors.

Authors:  Serena Zacchigna; Giovanni Papa; Andrea Antonini; Federico Novati; Silvia Moimas; Alessandro Carrer; Nikola Arsic; Lorena Zentilin; Valentina Visintini; Michele Pascone; Mauro Giacca
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

2.  VEGF gene therapy augments localized angiogenesis and promotes anastomotic wound healing: a pilot study in a clinically relevant animal model.

Authors:  C Kristian Enestvedt; Luke Hosack; Shelley R Winn; Brian S Diggs; Barry Uchida; Robert W O'Rourke; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

3.  SEC is an antiangiogenic virulence factor that promotes Staphylococcus aureus endocarditis independent of superantigen activity.

Authors:  Kyle J Kinney; Sharon S Tang; Xiao-Jun Wu; Phuong M Tran; Nikhila S Bharadwaj; Katherine N Gibson-Corley; Ana N Forsythe; Katarina Kulhankova; Jenny E Gumperz; Wilmara Salgado-Pabón
Journal:  Sci Adv       Date:  2022-05-11       Impact factor: 14.957

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.